

Supported in part by an educational grant from



**International Society of Gastrointestinal Oncology**

**2010 Gastrointestinal Oncology Conference**

**September 23–25, 2010**

**ABSTRACTS**

### **Gastric Cancer**

abstr 1029

**HER2 Status and Response to Adjuvant Chemotherapy in Resectable Gastric Cancer**

**Zoran Petrovic**

Department of GI Oncology, Clinic of Gastroenterology, VMA, Belgrade, Serbia

**Background:** Complete surgical resection of gastric cancer is potentially curable, but long-term survival is poor. We analyzed the effect of HER2 status on response to postoperative chemotherapy in patients with resectable gastric cancer.

**Methods:** Patients with gastric adenocarcinoma after potentially curative surgical resection were randomly assigned to follow-up alone or to systemic chemotherapy with six cycles of CapOx (oxaliplatin 85 mg/m<sup>2</sup> IV on day 1 and capecitabine 1,000 mg/m<sup>2</sup> days 1–14, repeated every 21 days in an ambulatory setting. In all patients we analyzed HER2 status after surgery.

**Results:** 118 patients were included. After surgery, 60 patients were assigned for postoperative chemotherapy and 58 patients for observation. After a median follow-up 36,8 months, 29 (48,3%) patients in the chemotherapy group and 31 (53,4%) patients in the follow-up group experienced recurrence. Of all 118 patients, 20 patients (33%) in the chemotherapy group and 17 patients (29%) in the observation group were HER2 positive.

**Conclusion:** Our results fail to provide proof an effect of adjuvant chemotherapy with CapOX on progression-free survival and overall survival. Also, the HER2 status had no effect on response or OS. The estimated effect of chemotherapy is modest and consistent with the results of adjuvant chemotherapy with other agents.